

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/292143808>

Infectious and coronary artery disease

Article in *ARYA Atherosclerosis* · January 2016

CITATIONS
10

READS
69

6 authors, including:



Mohammad Saeid Rezaee-Zavareh
Middle East Liver Disease Center

59 PUBLICATIONS 395 CITATIONS

[SEE PROFILE](#)



Amin Saburi
Baqiyatallah University of Medical Sciences

156 PUBLICATIONS 751 CITATIONS

[SEE PROFILE](#)



Mohsen Sadeghi Ghahrodi
Baqiyatallah University of Medical Sciences

11 PUBLICATIONS 17 CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



Evaluation of Emotional Intelligence and Its Relation to the Academic Achievement in Medical Students [View project](#)



shRNA-siRNA-cancer-Gene silencing-macrophage [View project](#)

Infectious and coronary artery disease

Mohammad Saeid Rezaee-Zavareh⁽¹⁾, Mohammad Tohidi⁽¹⁾, Amin Sabouri⁽¹⁾,
Mahdi Ramezani-Binabaj⁽¹⁾, Mohsen Sadeghi-Ghahrodi⁽²⁾, Behzad Einollahi⁽³⁾

Review Article

Abstract

BACKGROUND: Atherosclerotic event is one of the most causes of death in the world. Coronary artery disease (CAD) is one manifestation of atherosclerosis. It is well-known that several risk factors, such as diabetes mellitus (DM), smoking, hypertension (HTN), have effects on it. It is proposed that infection can lead to atherosclerosis or even make its process faster. Here, we discuss about the effect of some of infectious agents on the atherosclerosis and CAD.

METHODS: In this study, first we did a comprehensive search in PubMed, Scopus, and Science Direct using some related keywords such as atherosclerosis, CAD, myocardial infarction (MI), infection, and name of viruses and bacteria. After finding the related papers, we reviewed the correlation between some microbial agents and risk of CAD.

RESULTS: Literature has reported several infectious agents (viruses, bacteria, and parasites) that can be associated with risk of CAD. This association for some of them like *Helicobacter pylori* (*H. pylori*), *Chlamydia pneumoniae* (*C. pneumoniae*), and Cytomegalovirus (CMV) is a very strong. On the other hand, there are some other agents like influenza that still need to be more investigated through original studies. Furthermore, different mechanisms (general and special) have been reported for the association of each agent with CAD.

CONCLUSION: Based on the studies in databases and our literature review, it is so clear that some microbes and infectious agents can be involved in the process of atherosclerosis. Therefore, controlling each type of infections especially among people with a traditional risk factor for atherosclerosis should be taken into account for reducing the risk of CAD and atherosclerosis.

Keywords: Infection, Coronary Artery Disease, Atherosclerosis

Date of submission: 26 May 2015, *Date of acceptance:* 21 Sep 2015

Introduction

Development of plaques related to the athermanous in the inner layer of arteries is called atherogenesis. The traditional risk factors for the process of atherosclerosis can act on the different places of this process. For instance hypertension (HTN) as major risk factors for this process can increase the tension of arterial wall. It can prevent from appropriate repair process. It is proposed that cigarette smoking and diabetes can effect on the biology of the vasculature, but there are not enough details about their mechanisms.¹ It is said that traditional risk factors such as smoking, diabetes mellitus (DM), and HTN cannot be considered alone for all cases of atherosclerosis.²

Today atherosclerosis is considered as a chronic inflammatory disease of blood vessels. Two

mechanisms for the effect of inflammation on the atherosclerosis are considered. Direct mechanism is related to the inflammation at the site of vessel wall.³ Many studies in databases suggest that microbes have an important role in vascular disease and atherosclerosis.⁴ Infection in the vessel wall can act in the category of the direct mechanism. Infectious agents have effects on the formation of atherosclerotic plaque, making its process faster. Infectious agents can also lead to final complication of these plaques like plaque rupture and thrombosis.² The second and indirect mechanism is related to the inflammation at non-vasculature places that can lead to increase secretion of cytokines.³ Until now impact of many infectious agents on the atherosclerosis are investigated, and there are many original and even secondary articles

1- Researcher, Student Research Committee AND Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

2- Assistant Professor, Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

3- Professor, Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran

Correspondence to: Mohammad Saeid Rezaee-Zavareh, Email: dr_rezaee@live.com

in this field.² Effects of some microbes such as *Helicobacter pylori* (*H. pylori*), *Chlamydia pneumoniae* (*C. pneumoniae*), Cytomegalovirus (CMV), hepatitis C virus (HCV) on the atherosclerosis has been reviewed widely but evidence about some other agents seems to be inadequate. Table 1 shows some of the available meta-analyses in databases regarding the correlation of infection and atherosclerosis.

Materials and Methods

In this narrative review, electronic databases and resources including PubMed, Scopus and Science Direct and Google Scholar were searched using appropriate combination of some keywords like “atherosclerosis,” “coronary heart disease (CHD),” “cerebrovascular disease (CVDs),” “microbe,” “infection,” “bacteria,” “virus” and name of some infectious agents based on the literature review. Furthermore, in related papers, we investigated the references of them for finding other related papers. Before including each paper, we evaluated them regarding methodology and study design. After finding the related papers, the correlation between some microbial agents and coronary artery disease (CAD) were evaluated in 11 separate parts.

Results

H. pylori

Vcev et al.¹⁰ in a randomized, multicenter study with evaluation of 180 subjects (90 CAD and 90 healthy parsons as a control group) observed that *H. pylori* has more seroprevalence in patients group compared to control group. They also investigated the association between this infection and CAD risk factors and showed that body mass index, smoking, HTN, DM, total cholesterol, and socio-economic status in both groups of study have not a significant association with *H. pylori* infection. And at the end, they suggested more studies in this field. But Jin et al.¹¹ in their study showed that some risk factors for CAD [gender, age, smoking, and high-density lipoprotein (HDL) cholesterol] have a meaningful difference in patients with CAD (n = 175)

compared to control group (n = 88). They reported a non-significant difference between two groups about the presence of *H. pylori* infection.

In a cohort study, Zhu et al.¹² followed up 929 patients with CAD (antibodies to *H. pylori* were found in 56% of cases) for 3 years and investigated them for acute myocardial infarction (AMI) and death. Finally, they showed that there is no meaningful association between *H. pylori* infection and incidence of AMI or death and concluded that this infection cannot be a major risk factor for CAD, AMI or death.

In some studies, it has been proposed a mechanism for the association of *H. pylori* with CAD that we explain it with more details here. It is understood that hyperhomocysteinemia can be an important risk factor for CAD and atherosclerosis.¹³ This condition can result from inhibition of the methionine synthase reaction due to the low-level of folate serum.¹⁴ On the other hand, we know that *H. pylori* infection can result in low ascorbic acid level in gastric juice¹⁵ which reduces absorption of folate.¹⁶ Furthermore, there is a meaningful association between folate level of serum and CHD.¹⁷ Therefore, we think that effect of prescribing ascorbic acid on decreasing the atherosclerosis process can be studied and with consideration of all available data about the association of *H. pylori* and CAD, we suggest that these patients especially those with a conventional risk factor for CAD should take a good care for CAD. Another proposed mechanism for *H. pylori* infection is related to *H. pylori* strains with cytotoxin-associated gene A. However, a study revealed that colonization with this battery cannot considered as an independent risk factor for severe CAD.¹⁸ Power full studies like meta-analysis studies in a different aspect of this association like the progression of atheroma, development of CAD and its effect on risk factors of CAD is helpful about this issue. A meta-analysis in 2012 showed that there is an association between *H. pylori* infection and ischemic stroke⁶ while another one in 2014 rejected this correlation.¹⁹

Table 1. Some available meta-analyses regarding correlation of infection and atherosclerosis

First author	Publication year	Microorganism	Evaluated outcome	Reported results
Zhang et al. ⁵	2008	<i>H. pylori</i> (Cag A)	IS and CAD	Significantly associated
Wang et al. ⁶	2012	<i>H. pylori</i>	IS	Significantly associated
Chen et al. ⁷	2013	<i>C. pneumoniae</i>	CVD	Significantly associated
Huang et al. ⁸	2014	Hepatitis C	Carotid atherosclerosis	Significantly associated
Filardo et al. ⁹	2015	<i>C. pneumoniae</i>	Atherosclerosis	Significantly associated

H. pylori: *Helicobacter pylori*; *C. pneumoniae*: *Chlamydia pneumoniae*; CAD: Coronary artery disease; CVD: Cardiovascular disease; IS: Ischemic stroke

Streptococcal pneumonia

Eurich et al.²⁰ in a population-based cohort study investigated 6171 patients of community-acquired pneumonia. During the follow-up, they observed acute coronary syndrome (ACS) events in 175 patients. They showed that pneumococcal polysaccharide vaccination can reduce the ACS events (about 60%) in patients with pneumonia. There is a possible mechanism for this protective effect of pneumococcal vaccination based on an experimental study. The similarity between epitope of *S. pneumoniae* and oxidized low-density lipoprotein (Ox-LDL) propose a molecular mimicry theory so that pneumococcal vaccination can result in a reduction of anti-Ox-LDL immunoglobulins (Igs) and finally decrease in the atherosclerosis process.²¹

There is a possibility for hereditary component-2 deficiency (C2D) that can play a role for progression of atheroma. On the other hand, Jonsson et al.²² investigated 40 persons with C2D. They reported severe infection as the most clinical presentation for these patients. Septicemia or meningitis caused by *S. pneumonia* made up the majority of previous reported infections. Moreover, they also reported pneumonia and recurrent pneumonia in their follow-up of these patients.

Based on these studies, an association between *S. pneumonia* with CAD can be suggested but this association and its mechanism is still unclear and more original studies, and evidence is needed to clarify all aspect of this association.

C. pneumoniae

C. pneumoniae infection is another bacterial infection that is proposed for playing a role for developing CAD. In a cross-sectional study Haider et al.,²³ evaluated 63 patients with CVDs including angina and MI and 40 healthy subjects as control group for detection of *C. pneumoniae* IgA antibodies and interferon γ (IFN- γ) with enzyme-linked immunosorbent assays (ELISA). According to their observation *C. pneumoniae*, IgA was seen in 66.7% of subjects in control groups and in 41.4% in subjects in control groups. The mean amount of IFN- γ was 32.12 pg/ml in patients group compared to 11.32 pg/ml in control groups. An important finding in this study was about increased IFN- γ in patients group. We also know that the value of IFN- γ can be higher in patients with ACS and stable angina compared with healthy persons.²⁴ Hence, it can be said the *C. pneumoniae* can have some effects on the development of CAD especially

by elevation of IFN- γ values. However, there are some studies that concluded this relationship cannot be very strong. For example, Sadeghian et al.²⁵ by a case-control study investigated 30 patients with coronary atherosclerosis and the same number in the control group. They observed only one patient with positive polymerase chain reaction (PCR) for *C. pneumoniae* in cases group. In the control group, there were no positive cases.

Also, it has been showed that there is a cross reactivity between *Bartonella quintana* and *C. pneumoniae*. Hence, there is possibility that the association between *C. pneumoniae* and CAD can be related to the *B. quintana*. But, Badiaga et al.²⁶ in a case-control study demonstrated that *C. pneumoniae* is an independent risk factor for CAD and only in some cases there is a co-infection not cross-reactivity.

These differences must be evaluated in more powerful studies like a meta-analysis. For instance in a meta-analysis in 2013 a significant association between CVDs and serum specific IgG for *C. pneumoniae* has been reported.⁷ Different issues in this topic should be evaluated in other studies. One of them is related to the different methods (PCR, serological markers, culture from vascular tissue) that used in different studies. The other important problem is the use of standard method in studies.²⁷

Mycoplasma pneumoniae (M. pneumoniae)

Basinkevich et al.²⁸ measured antibodies and antigen to *M. pneumoniae* in patients with CHD and persons without it and demonstrated that there is more seropositivity for *M. pneumoniae* in cases group compared with control group. So, they concluded that this type of infection can be associated with CHD.

M. pneumoniae and *C. pneumoniae* usually is reported together in different studies related to CAD.^{28,29} Momiyama et al.³⁰ investigated the interaction of *M. pneumoniae* infection with chlamydial infection. They concluded that *M. pneumoniae* is a more prevalent in persons with CAD compared with control group and they showed that this prevalence can be dependent on co-infection by *M. pneumoniae* and *C. pneumoniae*. Therefore, this co-infection is considered as an important factor for development CAD.

For confirming the association of *M. pneumoniae* with CAD and also the interaction of *M. pneumoniae* infection with chlamydial infection, more original studies is still needed. But now consideration of reducing the CAD risk factors in

these patients should be noticed.

Human immunodeficiency virus (HIV)

Another important organism that is mentioned to have an association with atherosclerosis is HIV. Neumann et al.³¹ investigated 101 HIV-infected patients with coronary angiography and demonstrated that there is CAD in 59.1% of all patients. Also, it has been said that some factors like simultaneous infections with other viruses or vitamin D deficiency/insufficiency can make a stronger correlation between HIV infection and CAD.³² Escaut et al.³³ in a cohort of 840 patients showed that there were a higher proportion of coronary event in HIV-infected subjects and concluded that metabolic disturbances due to drugs and smoking of tobacco is the important factors for this association. Lai et al.³⁴ in their study demonstrated that long-term exposure to the antiviral therapy and use of cocaine is associated with the development of CAD. At this time, there are some studies proposed the relationship between HIV and CAD and each one suggests some factors affecting on this relationship so it seems that meta-analysis for doing subgroup analysis in this field can be more helpful. An available meta-analysis about this issue in 2009 revealed that HIV infection cannot be a strong risk factor for subclinical atherosclerosis.³⁵

CMV

Basinkevich et al.²⁹ in their study measured the level of IgM antibody to CMV in patients with MI, unstable angina, stable angina and in healthy subjects as control group and showed that seropositivity frequency is more in patients group compared with control group. Furthermore, there are some studies have shown the presence of CMV and its replication in the atherosclerotic plaque.³⁶ There is a mechanism that has been proposed for the effect of CMV in the process of atherosclerosis. It has been said that antibodies specific for CMV can trigger a pathway and induce genes expressing the molecules implicated in the activation of endothelial cell apoptosis that this damage to the endothelial cell can be consider for atherosclerotic pathogenicity.³⁷ It is proved that poor control of glucose level in type 2 diabetic patients can lead to developing CMV infection of arterial wall.³⁸ Another important issue is related to the existence of CMV infection in immunosuppressive patients like kidney transplant patients. This infection also is related to the development of atherosclerosis among kidney transplant patients.^{39,40} After all a

meta-analysis in 2012 with inclusion of 55 studies showed that CMV infection can be effective in the process of atherosclerosis.⁴¹

Herpes simplex virus type 1 (HSV-1) and 2

Al-Ghamdi⁴² for revealing the association of HSV-1 and atherosclerosis measured the level of IgG antibody specific for HSV-1 among 40 patients with acute and chronic CAD, 20 with peripheral arterial disease and 20 with cerebral stroke and compared it with 15 subjects as control group. In the results of this study, in spite of a high seropositivity for HSV, the seropositivity had not a statistically meaningful difference between the two groups. Also Sorlie et al.⁴³ reported that there is no association between HSV1 antibody level and CHD. Some studies have different results. For example, Siscovick et al.⁴⁴ in a nested case-control study observed that existence of antibody to HSV-1 can increase the risk of incident MI and CHD death 2 times in older patients. Some studies also proposed a mechanism for effect of HSV-1 on atherosclerosis process. A major receptor for Ox-LDL is lectin-like Ox-LDL receptor-1 (LOX-1) in the endothelial cell. It has been said that this receptor is more expressed in the atherosclerosis process and therefore there may be a possible role in the atherosclerosis for this receptor.⁴⁵

On the other hand, it has been shown that in HSV-1 infected patients, due to the more expression of LOX-1, the uptake of Ox-LDL will increase and therefore it can lead to activation and dysfunction of endothelial cells and eventually atherosclerosis.⁴⁶ But ultimately with consideration of this available data, we suggest more original studies and long-term follow-up of HCV-1 infected patients for a better understanding of association between HSV-1 and CAD. Sun et al. in a cross-sectional study with evaluation of 1244 subjects (488 with essential HTN and 756 normotensive) demonstrated that HSV-2 can be considered as an independent risk factor for HTN⁴⁷ and we know that HTN is a traditional risk factor for CAD. So, it can be supposed that HSV-2 can develop CAD by HTN. Also it has been shown that seropositivity of HSV-2 antibody can be related to the risk of death due to the CVD in the future.⁴⁸

Biopsies from CAD have been investigated for inflammatory cells and also for the antigen to HSV-2. And it is demonstrated that there is a meaningful correlation between the presence of antigen to HSV-2 and infiltrate.⁴⁹ But in some studies also reported that seropositivity to HCV-2 antibody is not different between ischemic heart disease (IHD)

patients compared with healthy subjects.⁵⁰ At this time, we need more original studies for clarifying the association of HSV-2 with atherosclerosis process and CAD.

Hepatitis viruses

Hepatitis viruses seem to be involved in the process of atherosclerosis. It has been shown that hepatitis A virus (HAV) can be related to the development of atherosclerosis process and therefore leading to CAD. Zhu et al.⁵¹ showed in their study that CAD has statistically more prevalence among HAV-infected patients compared with patients without HAV seropositivity. So according to this conclusion, prevalence of CAD and HAV infection should be associated to each other but the prevalence of HAV infection and CVD is not similar in different places.⁵² Furthermore, there are some studies with consideration of CAD prevalence have concluded that HAV infection cannot be a predictor for atherosclerosis and it's not related to CAD.^{53,54}

Ishizaka et al. in their study concluded that hepatitis B virus (HBV) is not associated with C-reactive protein (CRP) level and atherosclerosis. In contrast, HBV infection and seropositivity to HBV surface antigen has been proposed as a risk factor for developing atherosclerosis.⁵⁵ About involving HBV in atherosclerosis process, there are some reasons. Infection with HBV can have some extra liver manifestation like vasculitis and there are some evidences that show the presence of HBV in endothelial cells.^{56,57} Also, we know that chronic liver disease can lead to increase of oxidative stress level.⁵⁸ So by this ways, it seems that hepatitis B infection can help the atherosclerosis process. But it also has been said the effect of HBV on atherosclerosis is duo to the liver failure and it cannot be an independent risk factor for CAD.⁵⁹

Arcari et al.⁶⁰ in their cohort study with the investigation of 582 subjects concluded that HCV infection has not any relationship with AMI. Also Butt et al.⁶¹ showed that patients with HCV infection has a younger age, lower lipid level and lower HTN prevalence than healthy control subjects. Even after adjusting conventional risk factor for CAD they concluded that HCV infection can be associated with developing CAD. Another study in 2013, by Miyajima et al.⁶² demonstrates that HCV can be associated with mild atherosclerosis. We know that presence of inflammatory markers like CRP and interleukin-6 (IL6) can be a trigger for atherosclerosis process^{63,64} and on the other hand, it

has been shown that these markers have a more level in the HCV-infected patients.^{65,66} So, this can be a possible mechanism for developing atherosclerosis by HCV infection. Also a meta-analysis in 2012 showed that HCV infection is an independent risk factor for carotid atherosclerosis.⁸

Influenza A

It has been shown that level of IL-6 and IL-8 can increase due to infection of monocyte with influenza A\H1N1 and it can lead to systemic inflammation and further developing the atherosclerosis process.⁶⁷ Perhaps this can activate the second or indirect mechanism about the role inflammation in the process of atherosclerosis that we pointed it before. Some other studies have reported that infection with influenza (A or B) cannot be a risk factor for developing CAD.⁶⁸ on the other hand it is shown that vaccination against influenza can be a protective factor for developing atherosclerosis during the seasons related to the flu.^{69,70} of course this is soon to be used generally for the suspected CAD patients and its effect should be investigated in further studies. Also more studies about relationship of CAD and influenza are still needed.

Organism causes dental infection

Some studies have suggested that oral and dental infection can be an important risk factor for CAD.^{71,72} So that they have also mentioned some of the organisms that cause oral or dental infection can be found in the coronary arteries of patients with atherosclerosis. *Porphyromonas gingivalis*, *Actinobacillus actinomycetemcomitans*, *Prevotella intermedia*, *Tannerella forsythensis*, are microorganisms implicated in dental infection and also have been seen in the coronary artery biopsy samples.⁷³ Zhang et al.⁷⁴ also reported in their study some other microorganism like *T. forsythensis*, *Bacteroides forsythus*, *Campylobacter rectus*, *Fusobacterium nucleatum*, *Treponema spp.* and *Streptococcus sanguis* simultaneously in both coronary atherosclerotic plaques and subgingival plaque in patients with CAD.⁷⁴ Based on these studies, the association between these infections and CAD can be concluded and dental health in particular in patients with CAD risk factors should be considered.

Conclusion

Based on the studies in databases and our literature review, it is so clear that some microbes and

infectious agents can be involved in the process of atherosclerosis. Some agents still need more studies for investigation of their effects on atherosclerosis and also secondary studies is required in some other agents. We think that the infectious agents can be involved in both direct and indirect mechanisms of inflammation effect on the process of atherosclerosis. On the other hand, it is shown that some other agents like *H. pylori* have some especial mechanisms for affecting on the process of atherosclerosis. We believe that infection should be considered as an important risk factor for atherosclerosis. Therefore, controlling each type of infections especially among people with a traditional risk factor for atherosclerosis should be taken into account for reducing the risk of CAD and atherosclerosis.

Acknowledgments

Authors would like to thank the Student Research Committee of Baqiyatallah University of Medical Sciences for holding related workshops in the field of review articles which were very useful for this project.

Conflict of Interests

Authors have no conflict of interests.

References

1. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. *Nature* 2011; 473(7347): 317-25.
2. Pedicino D, Giglio AF, Galiffa VA, Cialdella P, Trotta F, Graziani F, et al. Infections, immunity and atherosclerosis: pathogenic mechanisms and unsolved questions. *Int J Cardiol* 2013; 166(3): 572-83.
3. Campbell LA, Rosenfeld ME. Infection and Atherosclerosis Development. *Arch Med Res* 2015; 46(5): 339-50.
4. Stassen FR, Vainas T, Bruggeman CA. Infection and atherosclerosis. An alternative view on an outdated hypothesis. *Pharmacol Rep* 2008; 60(1): 85-92.
5. Zhang S, Guo Y, Ma Y, Teng Y. Cytotoxin-associated gene-A-seropositive virulent strains of *Helicobacter pylori* and atherosclerotic diseases: a systematic review. *Chin Med J (Engl)* 2008; 121(10): 946-51.
6. Wang ZW, Li Y, Huang LY, Guan QK, Xu DW, Zhou WK, et al. *Helicobacter pylori* infection contributes to high risk of ischemic stroke: evidence from a meta-analysis. *J Neurol* 2012; 259(12): 2527-37.
7. Chen J, Zhu M, Ma G, Zhao Z, Sun Z. Chlamydia pneumoniae infection and cerebrovascular disease: a systematic review and meta-analysis. *BMC Neurol* 2013; 13: 183.
8. Huang H, Kang R, Zhao Z. Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis. *PLoS One* 2014; 9(9): e106376.
9. Filardo S, Di Pietro M, Farcomeni A, Schiavoni G, Sessa R. Chlamydia pneumoniae-Mediated Inflammation in Atherosclerosis: A Meta-Analysis. *Mediators Inflamm* 2015; 2015: 378658.
10. Vcev A, Nakic D, Mrden A, Mirat J, Balen S, Ruzic A, et al. *Helicobacter pylori* infection and coronary artery disease. *Coll Antropol* 2007; 31(3): 757-60.
11. Jin SW, Her SH, Lee JM, Yoon HJ, Moon SJ, Kim PJ, et al. The association between current *Helicobacter pylori* infection and coronary artery disease. *Korean J Intern Med* 2007; 22(3): 152-6.
12. Zhu J, Quyyumi AA, Muhlestein JB, Nieto FJ, Horne BD, Zalles-Ganley A, et al. Lack of association of *Helicobacter pylori* infection with coronary artery disease and frequency of acute myocardial infarction or death. *Am J Cardiol* 2002; 89(2): 155-8.
13. Wu Y, Huang Y, Hu Y, Zhong J, He Z, Li W, et al. Hyperhomocysteinemia is an independent risk factor in young patients with coronary artery disease in southern China. *Herz* 2013; 38(7): 779-84.
14. Mahalle N, Kulkarni MV, Garg MK, Naik SS. Vitamin B12 deficiency and hyperhomocysteinemia as correlates of cardiovascular risk factors in Indian subjects with coronary artery disease. *J Cardiol* 2013; 61(4): 289-94.
15. Ruiz B, Rood JC, Fontham ET, Malcom GT, Hunter FM, Sobhan M, et al. Vitamin C concentration in gastric juice before and after anti-*Helicobacter pylori* treatment. *Am J Gastroenterol* 1994; 89(4): 533-9.
16. Verlinde PH, Oey I, Hendrickx ME, Van Loey AM, Temme EH. L-ascorbic acid improves the serum folate response to an oral dose of [6S]-5-methyltetrahydrofolic acid in healthy men. *Eur J Clin Nutr* 2008; 62(10): 1224-30.
17. Braun RD. Serum folate and risk of fatal coronary heart disease. *JAMA* 1996; 276(15): 1222.
18. Rogha M, Dadkhah D, Pourmoghaddas Z, Shirneshan K, Nikvarz M, Pourmoghaddas M. Association of *Helicobacter pylori* infection with severity of coronary heart disease. *ARYA Atheroscler* 2012; 7(4): 138-41.
19. Yu M, Zhang Y, Yang Z, Ding J, Xie C, Lu N. Association between *Helicobacter pylori* infection and stroke: a meta-analysis of prospective observational studies. *J Stroke Cerebrovasc Dis* 2014; 23(9): 2233-9.
20. Eurich DT, Johnstone JJ, Minhas-Sandhu JK, Marrie TJ, Majumdar SR. Pneumococcal

- vaccination and risk of acute coronary syndromes in patients with pneumonia: population-based cohort study. *Heart* 2012; 98(14): 1072-7.
21. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between *Streptococcus pneumoniae* and oxidized LDL. *Nat Med* 2003; 9(6): 736-43.
 22. Jonsson G, Truedsson L, Sturfelt G, Oxelius VA, Braconier JH, Sjöholm AG. Hereditary C2 deficiency in Sweden: frequent occurrence of invasive infection, atherosclerosis, and rheumatic disease. *Medicine (Baltimore)* 2005; 84(1): 23-34.
 23. Haider M, Rizvi M, Malik A, Azam M, Rabbani MU. Acute and chronic *Chlamydia pneumoniae* infection and inflammatory markers in coronary artery disease patients. *J Infect Dev Ctries* 2011; 5(8): 580-6.
 24. Bergstrom I, Backteman K, Lundberg A, Ernerudh J, Jonasson L. Persistent accumulation of interferon-gamma-producing CD8+CD56+ T cells in blood from patients with coronary artery disease. *Atherosclerosis* 2012; 224(2): 515-20.
 25. Sadeghian MH, Yazdi SA, Ayatollahi H, Keramati MR, Ghazvini K, Rezai AR, et al. Is there any relationship between *Chlamydia pneumoniae* and coronary atherosclerosis among Iranians? *Niger Med J* 2013; 54(1): 40-4.
 26. Badiaga S, Paganelli F, Parola P, Beghin M, Barrau K, Eb F, et al. *Chlamydia pneumoniae*, but not *Bartonella quintana*, is associated with coronary heart disease: results of a French case-control study. *Clin Microbiol Infect* 2003; 9(4): 315-8.
 27. Boman J, Hammerschlag MR. *Chlamydia pneumoniae* and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. *Clin Microbiol Rev* 2002; 15(1): 1-20.
 28. Basinkevich AB, Shakhnovich RM, Martynova VR, Kolkova NI, Rakovskaia IV, Karazhas NV, et al. Role of *Chlamydia*, *Mycoplasma* and *Cytomegalovirus* infection in the development of coronary artery disease. *Kardiologiya* 2003; 43(11): 4-9.
 29. Maia IL, Nicolau JC, Machado MN, Maia LN, Takakura IT, Rocha PR, et al. Prevalence of *Chlamydia pneumoniae* and *Mycoplasma pneumoniae* in different forms of coronary disease. *Arq Bras Cardiol* 2009; 92(6): 405-8, 439.
 30. Momiyama Y, Ohmori R, Taniguchi H, Nakamura H, Ohsuzu F. Association of *Mycoplasma pneumoniae* infection with coronary artery disease and its interaction with chlamydial infection. *Atherosclerosis* 2004; 176(1): 139-44.
 31. Neumann T, Lulsdorf KA, Krings P, Reinsch N, Erbel R. Coronary artery disease in HIV-infected subjects. Results of 101 coronary angiographies. *Herz* 2011; 36(1): 18-23.
 32. Barakat MG, Arora RR. Coronary Artery Disease in the Human Immunodeficiency Virus Seropositive Population. *Am J Ther* 2016; 23(1): e224-e231.
 33. Escaut L, Monsuez JJ, Chironi G, Merad M, Teicher E, Smadja D, et al. Coronary artery disease in HIV infected patients. *Intensive Care Med* 2003; 29(6): 969-73.
 34. Lai S, Fishman EK, Lai H, Moore R, Cofrancesco J, Pannu H, et al. Long-term cocaine use and antiretroviral therapy are associated with silent coronary artery disease in African Americans with HIV infection who have no cardiovascular symptoms. *Clin Infect Dis* 2008; 46(4): 600-10.
 35. Hulten E, Mitchell J, Scally J, Gibbs B, Villines TC. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies. *Heart* 2009; 95(22): 1826-35.
 36. Izadi M, Fazel M, Saadat SH, Nasserri MH, Ghasemi M, Dabiri H, et al. Cytomegalovirus localization in atherosclerotic plaques is associated with acute coronary syndromes: report of 105 patients. *Methodist Debakey Cardiovasc J* 2012; 8(2): 42-6.
 37. Lunardi C, Dolcino M, Peterlana D, Bason C, Navone R, Tamassia N, et al. Endothelial cells' activation and apoptosis induced by a subset of antibodies against human cytomegalovirus: relevance to the pathogenesis of atherosclerosis. *PLoS One* 2007; 2(5): e473.
 38. Izadi M, Fazel M, Karbasi-Afshar R, Saadat SH, Nasserri MH, Jonaidi-Jafari N, et al. Glycemic control in type 2 diabetes mellitus prevents coronary arterial wall infection. *ARYA Atheroscler* 2014; 10(3): 141-6.
 39. Courivaud C, Bamoulid J, Chalopin JM, Gaiffe E, Tiberghien P, Saas P, et al. Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients. *J Infect Dis* 2013; 207(10): 1569-75.
 40. Ozdemir FN, Akgul A, Altunoglu A, Bilgic A, Arat Z, Haberal M. The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients. *Transplant Proc* 2007; 39(4): 990-2.
 41. Ji YN, An L, Zhan P, Chen XH. Cytomegalovirus infection and coronary heart disease risk: a meta-analysis. *Mol Biol Rep* 2012; 39(6): 6537-46.
 42. Al-Ghamdi A. Role of herpes simplex virus-1, cytomegalovirus and Epstein-Barr virus in atherosclerosis. *Pak J Pharm Sci* 2012; 25(1): 89-97.
 43. Sorlie PD, Nieto FJ, Adam E, Folsom AR, Shahar E, Massing M. A prospective study of cytomegalovirus, herpes simplex virus 1, and coronary heart disease: the atherosclerosis risk in

- communities (ARIC) study. *Arch Intern Med* 2000; 160(13): 2027-32.
44. Siscovick DS, Schwartz SM, Corey L, Grayston JT, Ashley R, Wang SP, et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults : the Cardiovascular Health Study. *Circulation* 2000; 102(19): 2335-40.
 45. Chen M, Masaki T, Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. *Pharmacol Ther* 2002; 95(1): 89-100.
 46. Chirathaworn C, Pongpanich A, Poovorawan Y. Herpes simplex virus 1 induced LOX-1 expression in an endothelial cell line, ECV 304. *Viral Immunol* 2004; 17(2): 308-14.
 47. Sun Y, Pei W, Wu Y, Jing Z, Zhang J, Wang G. Herpes simplex virus type 2 infection is a risk factor for hypertension. *Hypertens Res* 2004; 27(8): 541-4.
 48. Rupprecht HJ, Blankenberg S, Bickel C, Rippin G, Hafner G, Prellwitz W, et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. *Circulation* 2001; 104(1): 25-31.
 49. Raza-Ahmad A, Klassen GA, Murphy DA, Sullivan JA, Kinley CE, Landymore RW, et al. Evidence of type 2 herpes simplex infection in human coronary arteries at the time of coronary artery bypass surgery. *Can J Cardiol* 1995; 11(11): 1025-9.
 50. Jafarzadeh A, Nemati M, Tahmasbi M, Ahmadi P, Rezayati MT, Sayadi AR. The association between infection burden in Iranian patients with acute myocardial infarction and unstable angina. *Acta Med Indones* 2011; 43(2): 105-11.
 51. Zhu J, Quyyumi AA, Norman JE, Costello R, Csako G, Epstein SE. The possible role of hepatitis A virus in the pathogenesis of atherosclerosis. *J Infect Dis* 2000; 182(6): 1583-7.
 52. Cainelli F, Concia E, Vento S. Hepatitis A virus infection and atherosclerosis. *J Infect Dis* 2001; 184(3): 390-1.
 53. Auer J, Leitinger M, Berent R, Prammer W, Weber T, Lassnig E, et al. Hepatitis A IgG seropositivity and coronary atherosclerosis assessed by angiography. *Int J Cardiol* 2003; 90(2-3): 175-9.
 54. Ongey M, Brenner H, Thefeld W, Rothenbacher D. Helicobacter pylori and hepatitis A virus infections and the cardiovascular risk profile in patients with diabetes mellitus: results of a population-based study. *Eur J Cardiovasc Prev Rehabil* 2004; 11(6): 471-6.
 55. Ishizaka N, Ishizaka Y, Takahashi E, Toda EE, Hashimoto H, Ohno M, et al. Increased prevalence of carotid atherosclerosis in hepatitis B virus carriers. *Circulation* 2002; 105(9): 1028-30.
 56. Mason A, Wick M, White H, Perrillo R. Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. *Hepatology* 1993; 18(4): 781-9.
 57. Guillevin L, Lhote F, Gherardi R. The spectrum and treatment of virus-associated vasculitides. *Curr Opin Rheumatol* 1997; 9(1): 31-6.
 58. Sumida Y, Nakashima T, Yoh T, Kakisaka Y, Nakajima Y, Ishikawa H, et al. Serum thioredoxin elucidates the significance of serum ferritin as a marker of oxidative stress in chronic liver diseases. *Liver* 2001; 21(5): 295-9.
 59. Sung J, Song YM, Choi YH, Ebrahim S, Davey SG. Hepatitis B virus seropositivity and the risk of stroke and myocardial infarction. *Stroke* 2007; 38(5): 1436-41.
 60. Arcari CM, Nelson KE, Netski DM, Nieto FJ, Gaydos CA. No association between hepatitis C virus seropositivity and acute myocardial infarction. *Clin Infect Dis* 2006; 43(6): e53-e56.
 61. Butt AA, Xiaoqiang W, Budoff M, Leaf D, Kuller LH, Justice AC. Hepatitis C virus infection and the risk of coronary disease. *Clin Infect Dis* 2009; 49(2): 225-32.
 62. Miyajima I, Kawaguchi T, Fukami A, Nagao Y, Adachi H, Sasaki S, et al. Chronic HCV infection was associated with severe insulin resistance and mild atherosclerosis: a population-based study in an HCV hyperendemic area. *J Gastroenterol* 2013; 48(1): 93-100.
 63. Fan J, Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. *J Atheroscler Thromb* 2003; 10(2): 63-71.
 64. Libby P. Inflammation in atherosclerosis. *Nature* 2002; 420(6917): 868-74.
 65. Nascimento MM, Bruchfeld A, Suliman ME, Hayashi SY, Pecoits-Filho R, Manfro RC, et al. Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients. *Braz J Med Biol Res* 2005; 38(5): 783-8.
 66. Rios-Olivares E, Vila LM, Reyes JC, Rodriguez JW, Colon JH, Pagan NO, et al. Impaired cytokine production and suppressed lymphocyte proliferation activity in HCV-infected cocaine and heroin ("speedball") users. *Drug Alcohol Depend* 2006; 85(3): 236-43.
 67. Bouwman JJ, Visseren FL, Bosch MC, Bouter KP, Diepersloot RJ. Procoagulant and inflammatory response of virus-infected monocytes. *Eur J Clin Invest* 2002; 32(10): 759-66.
 68. Auer J, Leitinger M, Berent R, Prammer W, Weber T, Lassnig E, et al. Influenza A and B IgG seropositivity and coronary atherosclerosis assessed by angiography. *Heart Dis* 2002; 4(6): 349-54.
 69. Gurfinkel E, Mautner B. Secondary prevention of coronary artery disease. Flu vaccinations and new

evidence of the role of infection in acute coronary syndromes. *Rev Esp Cardiol* 2002; 55(10): 1009-12.

70. Lavalley P, Perchaud V, Gautier-Bertrand M, Grabli D, Amarenco P. Association between influenza vaccination and reduced risk of brain infarction. *Stroke* 2002; 33(2): 513-8.
71. Mattila KJ, Valtonen VV, Nieminen M, Huttunen JK. Dental infection and the risk of new coronary events: prospective study of patients with documented coronary artery disease. *Clin Infect Dis* 1995; 20(3): 588-92.
72. Higashi Y, Goto C, Hidaka T, Soga J, Nakamura S, Fujii Y, et al. Oral infection-inflammatory pathway, periodontitis, is a risk factor for endothelial dysfunction in patients with coronary artery disease. *Atherosclerosis* 2009; 206(2): 604-10.
73. Pucar A, Milasin J, Lekovic V, Vukadinovic M, Ristic M, Putnik S, et al. Correlation between atherosclerosis and periodontal putative pathogenic bacterial infections in coronary and internal mammary arteries. *J Periodontol* 2007; 78(4): 677-82.
74. Zhang YM, Zhong LJ, Liang P, Liu H, Mu LT, Ai SK. Detection of periodontal pathogenic bacteria DNA in coronary atheromatous plaques from patients underwent coronary artery bypass graft. *Zhonghua Xin Xue Guan Bing Za Zhi* 2008; 36(3): 215-8.

How to cite this article: Rezaee-Zavareh MS, Tohidi M, Sabouri A, Ramezani-Binabaj M, Sadeghi-Ghahrodi M, Einollahi B. **Infectious and coronary artery disease.** *ARYA Atheroscler* 2016; 12(1): ??-??.